HIV

The human immunodeficiency virus, commonly called HIV, is a retrovirus that primarily infects vital components of the human immune system such as CD4+ T cells, macrophages and dendritic cells. It also directly and indirectly destroys CD4+ T cells. As CD4+ T cells are required for the proper functioning of the immune system, when enough CD4+ cells have been destroyed by HIV, the immune system barely works, leading to AIDS. HIV also directly attacks certain human organs, such as the kidneys, the heart and the brain leading to acute renal failure, cardiomyopathy, dementia and encephalopathy. Many of the problems faced by people infected with HIV results from the failure of the immune system to protect them from certain opportunistic infections and cancers.

References

• {{note|Barré-Sinoussi}} Barré-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., Rozenbaum, W. and Montagnier, L. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) Science 220, 868-871 PMID 6189183
• {{note|Bentwich}} Bentwich, Z., Kalinkovich., A. and Weisman, Z. (1995) Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol. Today 16, 187-191 PMID 7734046
• {{note|Bukrinsky}} Bukrinsky M, Adzhubei A. (1999) Viral protein R of HIV-1. Rev Med Virol 9, 39-49 PMID 10371671
• {{note|Campbell2004}} Campbell GR, Pasquier E, Watkins J, Bourgarel-Rey V, Peyrot V, Esquieu D, Barbier P, de Mareuil J, Braguer D, Kaleebu P, Yirrell DL, Loret EP. (2004) The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J. Biol. Chem. 279, 48197-48204 PMID 15331610
• {{note|Campbell2005}} Campbell GR, Watkins JD, Esquieu D, Pasquier E, Loret EP and Spector SA (2005) The C-terminus of HIV-1 Tat modulates the extent of CD178 mediated apoptosis of T cells. J. Biol. Chem. In Press. PMID 16155003
• {{note|Carr}} Carr, J. K., Foley, B. T., Leitner, T., Salminen, M., Korber, B. and McCutchan, F. (1998) Reference Sequences Representing the Principal Genetic Diversity of HIV-1 in the Pandemic. In: Los Alamos National Laboratory (Ed) HIV Sequence Compendium, pp. 10-19
• {{note|Chan}} Chan, D. C. and Kim, P. S. (1998) HIV entry and its inhibition. Cell 93, 681-684 PMID 9630213
• {{note|Clerici}} Clerici, M., Balotta, C., Meroni, L., Ferrario, E., Riva, C., Trabattoni, D., Ridolfo, A., Villa, M., Shearer, G.M., Moroni, M. and Galli, M. (1996) Type 1 cytokine production and low prevalence of viral isolation correlate with long-term non progression in HIV infection. AIDS Res. Hum. Retroviruses. 12, 1053-1060 PMID 8827221
• {{note|Coakley}} Coakley, E., Petropoulos, C. J. and Whitcomb, J. M. (2005) Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis. 18, 9-15. PMID 15647694
• {{note|Coffin}} Coffin, J., Haase, A., Levy, J. A., Montagnier, L., Oroszlan, S., Teich, N., Temin, H., Toyoshima, K., Varmus, H., Vogt, P. and Weiss, R. A. (1986) What to call the AIDS virus? Nature 321, 10. PMID 3010128.
• {{note|DHHS2005adult}} DHHS (2005) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents April 7, 2005
• {{note|DHHS2005child}} DHHS (2005) Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection March 24, 2005
• {{note|Dybul}} Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., Pau, A. K., and the Panel on Clinical Practices for Treatment of HIV. (2002) Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 137, 381-433 PMID 12617573.
• {{note|Gao}} Gao, F., Bailes, E., Robertson, D. L., Chen, Y., Rodenburg, C. M., Michael, S. F., Cummins, L. B., Arthur, L. O., Peeters, M., Shaw, G. M., Sharp, P. M. and Hahn, B. H. (1999) Origin of HIV-1 in the chimpanzee Pantroglodytes troglodytes. Nature 397, 436-441 PMID 9989410
• {{note|Gelderblom}} Gelderblom, H. R. (1997) Fine structure of HIV and SIV. In: Los Alamos National Laboratory (Ed) HIV Sequence Compendium, 31-44.
• {{note|Gendelman}} Gendelman, H. E., Phelps, W., Feigenbaum, L., Ostrove, J. M., Adachi, A., Howley, P. M., Khoury, G., Ginsberg, H. S. and Martin, M. A. (1986) Transactivation of the human immunodeficiency virus long terminal repeat sequences by DNA viruses. Proc. Natl. Acad. Sci. U. S. A. 83, 9759-9763 PMID 2432602
• {{note|ICTVdB6106}} ICTVdB Descriptions. 61.0.6. Lentiviruses.
• {{note|ICTVdB61}} ICTVdB Descriptions. 61. Retroviridae.
• {{note|Jeang}} Jeang, K. T. (1996) In: Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos National Laboratory (Ed.) pp. III-3?III-18
• {{note|Kahn}} Kahn, J. O. and Walker, B. D. (1998) Acute Human Immunodeficiency Virus type 1 infection. N Engl J Med 331, 33-39 PMID 9647878.
• {{note|Kim}} Kim JB, Sharp PA. (2001) Positive transcription elongation factor B phosphorylates hSPT5 and RNA polymerase II carboxyl-terminal domain independently of cyclin-dependent kinase-activating kinase. J. Biol. Chem. 276, 12317-12323 PMID 11145967
• {{note|Knight}} Knight, S. C., Macatonia, S. E. and Patterson, S. (1990) HIV I infection of dendritic cells. Int Rev Immunol. 6,163-75 PMID 2152500
• {{note|Learmont}} Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS. (1999) Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 340, 1715-1722 PMID 10352163
• {{note|Lévy}} Lévy, J. A. (1993) HIV pathogenesis and long-term survival. AIDS 7, 1401-1410 PMID 8280406
• {{note|Morgan2002a}} Morgan, D., Mahe, C., Mayanja, B. and Whitworth, J. A. (2002a) Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study. BMJ 324, 193-196 PMID 11809639
• {{note|Morgan2002b}} Morgan, D., Mahe, C., Mayanja, B., Okongo, J. M., Lubega, R. and Whitworth, J. A. (2002b) HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 16, 597-6032 PMID 11873003
• {{note|MMWR2005}} MMWR weekly (2005) Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States January 21, 54 (RR02), 1-20
• {{note|Osmanov}} Osmanov, S., Pattou, C., Walker, N., Schwardlander, B., Esparza, J. and the WHO-UNAIDS Network for HIV Isolation and Characterization. (2002) Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J. Acquir. Immune. Defic. Syndr. 29, 184-190 PMID 11832690
• {{note|Piatak}} Piatak, M., Jr, Saag, M. S., Yang, L. C., Clark, S. J., Kappes, J. C., Luk, K. C., Hahn, B. H., Shaw, G. M. and Lifson, J.D. (1993) High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259, 1749-1754 PMID 8096089
• {{note|Pollard}} Pollard, V. W. and Malim, M. H. (1998) The HIV-1 Rev protein. Annu Rev Microbiol. 52, 491-532 PMID 9891806
• {{note|Popovic}} Popovic, M., Sarngadharan, M. G., Read, E. and Gallo, R. C. (1984) Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224, 497-500 PMID 6200935
• {{note|Quiñones-Mateu}} Quiñones-Mateu, M. E., Mas, A., Lain de Lera, T., Soriano, V., Alcamí, J., Lederman, M. M. and Domingo, E. (1998) LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. Virus Research 57, 11-20 PMID 9833881
• {{note|Reeves}} Reeves, J. D. and Doms, R. W. (2002) Human immunodeficiency virus type 2. J. Gen. Virol. 83, 1253-1265 PMID 12029140
• {{note|Siegfried}} Siegfried N, Muller M, Deeks J, Volmink J, Egger M, Low N, Walker S, Williamson P. (2005) HIV and male circumcision--a systematic review with assessment of the quality of studies. Lancet Infect Dis 5, 165-173 PMID 15766651
• {{note|Strebel}} Strebel, K (2003) Virus-host interactions: role of HIV proteins Vif, Tat, and Rev. AIDS 17 Suppl 4, S25-S34 PMID 15080177
• {{note|Tang}} Tang, J. and Kaslow, R. A. (2003) The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy. AIDS 17, S51-S60 PMID 15080180
• {{note|Thomson}} Thomson, M. M., Perez-Alvarez, L. and Najera, R. (2002) Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis. 2, 461-71 PMID 12150845
• {{note|UNAIDS}} UNAIDS How can HIV be transmitted]
• {{note|UNAIDS2004}} UNAIDS (2004) AIDS epidemic update December 2004
• {{note|Xiao}} Xiao, H., Neuveut, C., Tiffany, H. L., Benkirane, M., Rich, E. A., Murphy, P. M. and Jeang, K. T. (2000) Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc. Natl. Acad. Sci. U. S. A. 97, 11466-11471 PMID 11027346
• {{note|WHO2001}} WHO (2001) WHO/AFRO Press Release from the 51st Session of the WHO regional committee for Africa.
• {{note|WHO2003}} WHO (2003) Scaling up retroviral therapy in resource limited settings
• {{note|WHO2005}} WHO (2005) 26 July WHO/UNAIDS statement on South African trial findings regarding male circumcision and HIV
• {{note|Wyatt}} Wyatt, R. and Sodroski, J. (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884-1888 PMID 9632381
• {{note|Zheng}} Zheng, Y. H., Lovsin, N. and Peterlin, B. M. (2005) Newly identified host factors modulate HIV replication. Immunol Lett. 97, 225-234 PMID 15752562